コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 the phase 3 development of grazoprevir plus elbasvir.
2 red treatment group received grazoprevir and elbasvir.
3 n, 8 or 12 weeks of treatment, and dosage of elbasvir.
4 oing phase 3 development of grazoprevir plus elbasvir.
5 ein 5A (HCV NS5A) inhibitors velpatasvir and elbasvir.
7 eceive 12 weeks of grazoprevir (100 mg) plus elbasvir (20 mg or 50 mg) with or without ribavirin (arm
8 l, once-daily, fixed-dose grazoprevir 100 mg/elbasvir 50 mg for 12 weeks, stratified by fibrosis and
9 ll patients received grazoprevir 100 mg plus elbasvir 50 mg in a fixed-dose combination tablet once d
10 l trial of grazoprevir 100 mg once daily and elbasvir 50 mg once daily coadministered with weight-bas
11 e enrolled at 68 centres worldwide to either elbasvir 50 mg plus grazoprevir 100 mg once per day for
12 t group) or placebo for 12 weeks followed by elbasvir 50 mg plus grazoprevir 100 mg once per day for
13 ts to receive grazoprevir (100 mg daily) and elbasvir (50 mg daily) with or without ribavirin for 12
14 mg once daily) and an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg
15 o 8 or 12 weeks of grazoprevir (100 mg) plus elbasvir (50 mg) with or without ribavirin (arms B1-3) a
16 evir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment gro
17 (450 mg/day); grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day); or
18 00 mg/day); or grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day), acc
21 HCV NS3/4A protease inhibitor) combined with elbasvir (an HCV NS5A inhibitor) with or without ribavir
24 herapy with grazoprevir (in combination with elbasvir, an inhibitor of HCV NS5A protein) showed that
27 with HCV genotype 1a infection who received elbasvir and grazoprevir for 12 weeks, baseline HCV gene
28 s (n = 6), an intensified 16-week regimen of elbasvir and grazoprevir plus ribavirin could increase e
29 NS5A polymorphisms, all 26 who received the elbasvir and grazoprevir regimens recommended in prescri
30 om selected phase 2 and 3 clinical trials of elbasvir and grazoprevir, with and without ribavirin.
31 lyses of drug resistance data from trials of elbasvir and grazoprevir, with and without ribavirin.
35 ly efficient synthesis of HCV drug candidate elbasvir, and has been applied to the synthesis of chira
37 with daclatasvir, velpatasvir, pibrentasvir, elbasvir, and sofosbuvir was measured using the S52 Delt
39 ss sensitive to daclatasvir, ledipasvir, and elbasvir, but equally sensitive to ombitasvir, velpatasv
42 (HCV) guidelines do not recommend the use of elbasvir (EBR)/grazoprevir (GZR) in postliver transplant
45 were enrolled and received grazoprevir plus elbasvir for 12 weeks, all of whom completed follow-up a
46 udy was to assess the safety and efficacy of elbasvir/grazoprevir (EBR/GZR) in patients with inherite
47 nts were randomized ( ribavirin) to LDV/SOF, elbasvir/grazoprevir (EBR/GZR), and paritaprevir/ritonav
48 R) (velpatasvir/sofosbuvir) and Zepatier(R) (elbasvir/grazoprevir) could be further optimized to achi
49 igate the efficacy and safety of grazoprevir-elbasvir guided by baseline resistance-associated substi
50 d tolerability of grazoprevir (MK-5172) plus elbasvir (MK-8742) in patients with HCV and HIV co-infec
51 NS3/4A protease inhibitor) and two doses of elbasvir (MK-8742; HCV NS5A inhibitor) in patients with
52 mediate treatment group with grazoprevir and elbasvir (n=111) or the deferred treatment group (n=113)
53 ce for the fixed-dose combination regimen of elbasvir plus grazoprevir for 12 weeks and support use o
54 he C-SURFER study, therapy with the all-oral elbasvir plus grazoprevir regimen for 12 weeks in patien
55 regimen (ten [71%] of 14), grazoprevir plus elbasvir plus uprifosbuvir 300 mg regimen (11 [69%] of 1
56 egimen (11 [69%] of 16), or grazoprevir plus elbasvir plus uprifosbuvir 450 mg regimen (nine [60%] of
57 ions of daclatasvir, ledipasvir, ombitasvir, elbasvir, ruzasvir, velpatasvir, and pibrentasvir in cul
58 f the 122 patients receiving grazoprevir and elbasvir, six were excluded from the primary efficacy an
59 inhibitor grazoprevir and the NS5A inhibitor elbasvir together with ribavirin in treatment-experience
61 on of a key intermediate in the synthesis of Elbasvir, which is a novel therapy for the treatment of
63 domised controlled trial of grazoprevir plus elbasvir with or without ribavirin in patients with HCV;
65 open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin; here we report findi
67 s treated for 12 weeks with grazoprevir plus elbasvir without ribavirin, 97% (95% CI 82-100, 28/29) o